Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor

An immune checkpoint, subject technology, applied in the field of oncology

Pending Publication Date: 2021-09-07
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
View PDF33 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, only some patients respond to treatment with immune checkpoint inhibitors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
  • Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
  • Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0007] The inventors have worked with two cohorts of patients: 1) the checkpoint cohort (CPP: 2015-08-04-MS2) established at Georges Pompidou Europea Hospital, including all patients who received immunotherapy (anti-PD-1 / PD-L1) treated patients, and blood and tissue samples were collected after obtaining the patient's consent. Twenty-seven renal cell carcinoma patients from this cohort were included in this study. Twenty-two of the patients had clear cell renal carcinoma. 2) Another set of specimens came from the Preinsut clinical study, in which patients with renal cell carcinoma received two cycles of sunitinib before nephrectomy [8]. Twenty-seven patients from this cohort were also included in this study.

[0008] The inventors have identified a soluble marker, CD27, present in the plasma of renal cell carcinoma patients, whose pretreatment concentrations were predictive of anti-PD-1 / PD-L1 responses. This marker is more like a predictive marker of response to anti-PD1 / P...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to use of soluble CD27 as a biomarker to predict the reponse to an immune checkpoint inhibitor treatment. Inventors have worked with two cohorts of patients and have identified a soluble marker, CD27, present in the plasma of patients with renal cell cancer whose pre-treatment concentrations predict the response to anti-PD-1 / PD- L1. This marker appears more as a predictive marker of response to anti-PD1 / PD-L1 treatment, than as a prognostic marker. Indeed, it is not associated with better survival in patients with metastatic renal cell cancer treated with an antiangiogenic agent. This marker is not correlated with conventional clinical markers of severity that classify patients with metastatic renal cancer.

Description

technical field [0001] The present invention belongs to the field of oncology. More specifically, the present invention relates to methods and compositions for determining whether a subject with cancer will respond to immune checkpoint inhibitor therapy. Background technique [0002] An anti-PD-1 antibody (nivolumab) has been approved for the second-line treatment of metastatic renal cell carcinoma tumors, and a phase 3 study showed superiority over anti-angiogenic therapy (everolimus)[ 1]. Twenty-five percent of patients responded to this treatment, with a survival advantage of 5.5 months compared with standard treatment. [0003] To date, traditional biomarkers such as PD-L1 or mutational burden or intratumoral CD8+ T cell infiltration cannot predict response to this immunotherapy treatment in patients with metastatic RCC [1-3]. [0004] In our team's previous study, we found that the co-expression of PD-1 and Tim-3 cells on CD8+ T cells was associated with poor prognos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/57488G01N2333/70578G01N2800/52G01N33/5011
Inventor E·塔托尔N·本·哈默达S·奥达德N·伊派尔拉德
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap